Video 16 Jul 2024 Quarterly Report – Period to 30 June 2024 Orthocell has today published its Quarterly Report for the period ended 30 June 2024. Orthocell
Company News 11 Jul 2024 Orthocell Receives Regulatory Approval to Commence Sales of Striate+™ in Canada Orthocell has received a Medical Device Licence from Health Canada, allowing the commencement of sales of its market leading dental… Orthocell
Media 10 Jul 2024 The Australian Business Review | Investors are all ears as Orthocell’s nerve and tissue solutions deliver record revenue News of Orthocell's record-breaking quarterly and full year revenue has been published in a Special Report in The Australian Business… Orthocell
Media 10 Jul 2024 Business News | Orthocell posts record revenue Orthocell's record revenue for FY24 has been reported in Business News. Orthocell
Media 10 Jul 2024 Proactive Interview | Record-breaking revenue for FY24 Orthocell Managing Director, Paul Anderson, spoke with Jonathan Jackson at Proactive to discuss the Company's record-breaking revenue for the June… Orthocell
Company News 09 Jul 2024 Orthocell Continues Impressive Growth with Record Quarterly and Yearly Revenue Achieved Orthocell has announced that it has recorded impressive sales growth across its product portfolio, with total revenue for FY24 of $6.72million… Orthocell
Company News, Media 14 Jun 2024 Petra Capital Research Report | June 2024 Petra Capital has released research report, forecasting Orthocell’s potential to reach A$1.28 per share. Orthocell
Company News 11 Jun 2024 Orthocell applies for TGA market approval for SmrtGraft™ Orthocell has applied to the Therapeutic Good Administration (TGA) for Australian market approval for its SmrtGraft™ tendon repair device, in… Orthocell
Company News 30 Apr 2024 Remplir™ nerve repair study published in peer-reviewed clinical journal Orthocell has announced that results from the Remplir™ nerve regeneration clinical trial have been published in a high profile clinical… Orthocell
Company News 15 Apr 2024 Orthocell receives $3.05m R&D tax incentive refund Orthocell has announced that it has received a Research and Development (R&D) Tax Incentive refund of A$3,051,483 for the financial… Orthocell
